AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 262 min read$ALAB

Mazzara Philip sold $232K of ALAB

Mazzara Philip (General Counsel and Secretary) sold 796 shares of Astera Labs, Inc. (ALAB) at $291.03 ($0.23M total) on 2026-05-21.

Original reporting
SEC EDGAR · Mazzara Philip
Published May 26, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The main tradable element is sentiment around insider behavior (selling) rather than any operational or financial update.

02

Market read

Traders may briefly reassess ALAB sentiment due to insider selling, but there is no fundamental company catalyst in the filing details provided.

03

What to watch

Check for clustering of subsequent Form 4s, changes in total insider ownership, and whether the sale coincides with option exercises or vesting-related liquidity needs.

Relevance 6/10Timing: Immediate (new Form 4 filed 2026-05-26; tradeable as a sentiment/positioning signal).

Background

The article is a SEC Form 4 disclosure of an officer’s direct open-market sale of Astera Labs shares.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs (ALAB) disclosed an open-market sale by its General Counsel/Secretary (S) of 796 shares for ~$231.7K on 2026-05-21.

Expected impact

Likely limited near-term impact; any reaction should fade unless follow-on filings show sustained selling.

Evidence & confidence

This is a Form 4 insider transaction (not earnings/M&A/regulatory). The filing notes no pre-arranged 10b5-1 plan, which can increase short-term interpretive risk, but the disclosed size is relatively small and does not indicate a company event.

Market effects

Sector

Minimal; single-company insider sale typically does not reset sector fundamentals.

Regional

None indicated; US-listed issuer filing only.

Global

None indicated; no cross-border deal/regulatory event mentioned.

Counterpoint

What could challenge this read

Insider sales can be routine for diversification/taxes; absence of a stated 10b5-1 plan does not necessarily imply negative outlook.

Key entities

  • issuer
    Astera Labs, Inc.

    Subject of the Form 4 insider transaction; General Counsel/Secretary sold 796 shares for ~$231.7K.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALAB insider trading history →

Related articles

OCT 9
$ALABMed

Astera Labs Stock Fell 9% in a Day as an OpenAI Revenue Report Hit Chip Stocks. Here’s Where the Stock Could Go by 2030

Astera Labs (ALAB) stock dropped 9.21% to $347.05 on October 8, following a broader chip sector sell-off triggered by OpenAI's lower-than-expected revenue report. The company launched Aries 7, its PCIe 7 signal conditioning portfolio. Despite a 23% rise in 2026 revenue forecasts to $1.91B, free cash flow fell 49.6% YoY to $67.21M, raising concerns. Analysts' target prices range from $390 to $850, with a potential total return of 146%.

finance.yahoo.com2 min
OCT 7
$ALABMed

Why is Astera Labs stock sliding today?

Astera Labs (ALAB) stock dropped 5.0% after Zacks Research downgraded it from 'strong buy' to 'hold', following a 10% surge on S&P 500 inclusion speculation. Insider selling and high valuation also pressured the stock, with broader market declines adding to the downturn. Competitors like Marvell Technology intensify the competitive landscape. The stock remains sensitive to macroeconomic factors and analyst commentary.

investing.com2 min
OCT 6
$ALABHigh

Why is Astera Labs stock surging today?

Astera Labs (ALAB) stock surged 9.5% to $396.82, with traders anticipating its inclusion in the S&P 500. The company reported Q2 revenue of $392.4M, beating estimates, and guided Q3 revenue to $540M–$560M. Analysts, including Fubon, have upgraded the stock, with a $500 price target. The S&P 500 and Nasdaq each rose 0.7% today.

investing.com2 min
SEP 16
$ALABMed

ALAB Stock Holds Support As High Valuation Tests Traders

Astera Labs Inc. (ALAB) stock rose 6.54% due to strong AI infrastructure demand. The company reported $392.4M in quarterly revenue, $153.1M in net income, and $67.2M in free cash flow. ALAB trades at 127x earnings and 37x sales, with a strong balance sheet but high valuation concerns. Traders are watching key price levels around $262–$265 and $272–$275.

stockstotrade.com2 min
SEP 16
$ALABMed

ALAB Broadens Leo Portfolio: Can It Stay Ahead of MRVL & CRDO?

Astera Labs (ALAB) reported record Q2 2026 revenue growth, driven by AI connectivity products. The company expanded its Leo CXL memory controller portfolio, gaining hyperscaler traction. Q3 2026 revenue is expected between $540M and $560M. Competitors Marvell (MRVL) and Credo (CRDO) are also advancing in AI connectivity. ALAB shares rose 51.8% YTD, with a forward P/S of 16.16X.

theglobeandmail.com2 min